Talys

Quick links to important sections

Talys

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Talys

Quick Facts

Property Description
Active ingredient Tadalafil
Form Oral film-coated tablet
Pharmacological class Phosphodiesterase type 5 (PDE5) inhibitor
General purpose To promote smooth muscle relaxation and local blood flow
Origin Synthetic small-molecule compound

What is Talys and What is its Pharmacological Class?

Talys is a prescription-only medication defined by its active chemical substance, Tadalafil (INN). This compound is classified within the specific pharmacological group of Phosphodiesterase type 5 (PDE5) inhibitors, a categorization for selectively modulating enzyme activity rather than acting as a general-purpose vasodilator. Tadalafil is a synthetic small-molecule compound and is typically supplied as a single-component product for oral use.

Composition and Unique Pharmaceutical Form

The medicine is supplied for oral administration as a film-coated tablet, containing the active ingredient, Tadalafil, combined with standard pharmaceutical excipients. A key differentiating characteristic of Tadalafil within the PDE5 inhibitor class is its remarkably prolonged terminal half-life, averaging approximately 17.5 hours in healthy subjects. This extended half-life results in a notable long duration of action compared to similar compounds, offering flexible scheduling options.

General Purpose and Physiological Action

The general therapeutic purpose of Talys is to improve physiological function by promoting smooth muscle relaxation and resultant vasodilation (vessel widening) in specific vascular beds. It achieves this by selectively blocking the PDE5 enzyme, which allows the natural chemical messenger cGMP to accumulate. This physiological effect—the resulting increase in local blood flow—is the primary functional benefit of Tadalafil. As a PDE5 inhibitor, it works by increasing blood flow, providing a mechanism to address physiological issues related to impaired circulation and elevated smooth muscle tension.

Regulatory References

  1. official drug information resources

What side effects are possible with Talys?

Possible Side Effects and Safety Information

The safety profile of Talys (Tadalafil) is officially documented by government regulatory agencies (such as the FDA and EMA) through classification by frequency and the body systems affected. These adverse reactions are categorized to reflect the expected physiological responses observed during clinical trials and postmarketing surveillance.

Frequency-Classified Adverse Reactions

The most common adverse reactions reported in regulatory documentation—those classified as Most Common (ge2%)—include headache, dyspepsia (indigestion), back pain, myalgia (muscle aches), nasal congestion, flushing, and pain in limb. Dizziness is also listed as a common effect (1–10%). These events primarily affect the Nervous, Gastrointestinal, Musculoskeletal, and Vascular System-Organ Classes.

Serious Adverse Reactions and Constraints

Official labels address several serious adverse reactions, often identified in postmarketing surveillance, including Priapism (an erection lasting longer than four hours), sudden decrease or loss of hearing, and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION), which can lead to sudden vision loss. Severe hypersensitivity reactions are also documented.

Use of Tadalafil is contraindicated with all forms of organic nitrates and guanylate cyclase (GC) stimulators due to the risk of severe hypotension. Furthermore, use is generally not recommended in individuals with severe hepatic impairment, and caution is required for patients with severe renal impairment or certain recent cardiovascular events.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose Scope

Domain Official Regulatory Statement
Documented Overdose Presentations Symptoms observed following high-dose exposure were similar to those reported at lower therapeutic doses [Official Labeling]. Clinical study experience includes single doses up to 500 mg and multiple daily doses up to 100 mg.
Physiological Systems Affected Events requiring urgent action involve the cardiovascular system (anginal chest pain), ocular system (sudden loss of vision), auditory system (sudden loss of hearing), and local effects (priapism).
Population-Specific Overdose Notes Hemodialysis contributes negligibly to tadalafil elimination [Official Labeling].

Emergency Actions and Supportive Measures

Classification Type Official Regulatory Statement
Management Strategy Standard supportive measures should be adopted as required. Symptomatic treatment is the recommended approach. No specific antidote is known for Tadalafil overdose [Official Labeling].
Monitoring Constraints If the administration of nitrates is medically necessary, it must occur under close medical supervision and appropriate hemodynamic monitoring, and only at least 48 hours after the last Tadalafil dose [Official Labeling].

When Immediate Medical Help Is Required (Label-Derived Phrasing Only):

Regulatory documents mandate that individuals seek emergency treatment immediately if an erection lasts for more than 4 hours. Immediate medical care must be sought for sudden loss of vision or for the onset of anginal chest pain. Prompt medical attention is also required for a sudden decrease or loss of hearing [Official Labeling Warnings].


Connection to the Overall Overdose Profile:

Regulatory documents define the Tadalafil overdose profile by confirming that high-dose exposure presents non-specific symptoms and by creating explicit regulatory triggers for seeking immediate medical help. This structure mandates urgent attention for specific, severe events like priapism, sudden vision loss, or chest pain, thereby establishing the conditions under which emergency medical response is officially required according to the label.

Therapeutic Uses of Talys

What Talys Treats: Main Uses and Benefits

Talys (Tadalafil) is commonly used across distinct therapeutic domains, all involving supportive management of symptoms linked to organ-specific functional stress. The medication is indicated in clinical settings to address several conditions, including Erectile Dysfunction (ED), the disruptive symptoms of Benign Prostatic Hyperplasia (BPH), and Pulmonary Arterial Hypertension (PAH).

Talys is relevant for managing symptom clusters that create noticeable physiological strain, such as voiding difficulties and the inability to achieve an erection. It provides support that helps ease the overall symptom burden, contributing to improved comfort during symptomatic periods. This application may assist with maintaining functional stability by supporting the ability to engage in exercise or supporting key physiological functions.


Quick Fact: Relief for Impaired Function
Primary Focus Symptomatic management of sexual function impairment and urinary tract symptoms (LUTS).
Key Benefit Supports functional stability and helps ease the overall symptom burden.
Clinical Context Used in conditions characterized by periods of heightened symptoms and functional deficit.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

This information details the officially documented criteria defining who is eligible to use Talys, strictly based on authoritative government regulatory documents.

Eligibility Scope

Talys is approved for use in adult men (18 years and older). Pediatric use (under 18) has not been evaluated and is not established. Use is not recommended for patients with severe hepatic impairment (Child-Pugh Class C) or for patients with severe renal impairment (creatinine clearance <30 mL/ min) when considering once-daily dosing.


Groups Who Must Not Use Talys (Contraindications)

Official labeling establishes several strict contraindications where the medicine must not be used:

  • Organic Nitrates: Patients using any form of organic nitrate medicine, either regularly or intermittently, must not use Talys, as this combination can cause a severe drop in blood pressure.
  • Cardiovascular Status: The drug is contraindicated in men for whom sexual activity is inadvisable due to their underlying cardiovascular condition.
  • Vision Loss History: Patients with a known history of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION), resulting in vision loss in one or both eyes, are contraindicated.
  • Hypersensitivity: Individuals with a known serious hypersensitivity reaction to the drug or any of its components are excluded from use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official drug labels specify interaction constraints based on pharmacokinetic effects, metabolic pathways, and pharmacodynamic properties.

Contraindicated Combinations

Co-administration of Tadalafil is contraindicated with two specific substance classes due to the risk of potentiated blood pressure lowering. These include all forms of Organic Nitrates (due to additive vasodilation) and Guanylate Cyclase (GC) Stimulators, such as Riociguat.

Pharmacokinetic Alterations

Tadalafil is primarily cleared through the CYP3A4 metabolic enzyme. Concomitant administration of potent CYP3A4 inhibitors (e.g., Ketoconazole, Ritonavir) results in a formally documented increase in systemic exposure (AUC) of Tadalafil. Conversely, potent CYP3A4 inducers (e.g., Rifampin) decrease Tadalafil exposure.

Other Documented Interactions

Interaction Type Interacting Substance / Category
Additive Hypotension Alpha-Blockers and general Antihypertensive Agents
Additive Hypotension Substantial amounts of Alcohol
Increased Exposure Grapefruit Juice (via CYP3A4 inhibition)

Regulatory Restrictions

Official labeling mandates a minimum of 48 hours must elapse after the last dose of Tadalafil before a patient may receive a nitrate-containing medicine. Furthermore, co-administration with other PDE5 inhibitors is advised to be avoided. The systemic exposure of Tadalafil is also formally noted to be increased in populations with severe renal impairment.

Mechanism of Action

The action of Tadalafil is defined by its selective molecular interaction with the target enzyme, initiating a cascade that alters vascular tone. The mechanism operates entirely at the biological level, influencing cellular processes that govern local blood flow.

Selective Inhibition of the PDE5 Enzyme

The primary mechanism involves acting as a selective competitive inhibitor of the enzyme Phosphodiesterase type 5 ( PDE5), which is prevalent in arterial smooth muscle. By blocking this enzyme, the drug prevents the hydrolysis of the crucial cellular messenger cGMP (cyclic Guanosine Monophosphate), leading to its intracellular accumulation.

Augmentation of the Nitric Oxide ( NO) Cascade

Tadalafil acts to amplify the natural Nitric Oxide ( NO) signaling cascade, as its action is dependent on the prior release of NO. The increased cGMP levels, stabilized by PDE5 inhibition, activate an enzyme that triggers a reduction in intracellular calcium, which directly facilitates smooth muscle relaxation.

Local Vasodilation and Increased Tissue Perfusion

The subsequent relaxation of the smooth muscle surrounding the blood vessels results in localized vasodilation (vessel widening), a core physiological consequence. This mechanism leads directly to increased blood flow (perfusion) in the targeted tissues, which represents the primary physiological consequence of PDE5 inhibition.

Dosage and Administration Information

How to Use Talys: Administration Guidelines

Talys (Tadalafil) administration follows defined protocols, outlining specific dosing schedules and administration protocols based on the condition being managed. The medicine is supplied for oral administration as a film-coated tablet.


Dosing Regimens

Dosing recommendations vary by indication; the following regimens are established for this medication.

Indication Use Pattern Standard Dose Maximum Frequency
Erectile Dysfunction (ED) As-Needed Starting dose of 10 mg Once per day
Erectile Dysfunction (ED) Once-Daily Maintenance dose of 5 mg Once per day
Benign Prostatic Hyperplasia (BPH) Once-Daily Fixed dose of 5 mg Once per day
Pulmonary Arterial Hypertension (PAH) Once-Daily Fixed dose of 40 mg Once per day

Administration Conditions and Restrictions

Talys tablets may be taken with or without food for all approved uses, providing flexibility in daily intake. For proper administration, the film-coated tablet must be swallowed whole with water and should not be crushed, split, or chewed.

Patients taking the once-daily regimen should take the dose at approximately the same time each day. If a dose is missed, it is recommended to take the next dose at the regularly scheduled time and not doubling the dose to compensate. For patients with severe renal or hepatic impairment, use of the once-daily regimen is generally not recommended, and dose limits apply to as-needed use. The 40 mg dose for PAH must be taken as a single administration and not divided.

Recent Clinical Evidence

Research evidence / Overview of Studies for Talys

The official research evidence for Talys (Tadalafil) is derived primarily from carefully designed Randomized Controlled Trials (RCTs), systematic reviews, and integrated analyses. These studies were conducted to explore how Tadalafil was studied for measured functional outcomes in patients with specific approved conditions. The findings describe group patterns and contribute to the broader evidence landscape, but research does not determine whether an individual will respond similarly.


Evidence for Use in Erectile Dysfunction (ED)

The evidence base for Tadalafil in this setting is founded on numerous short-term RCTs that compared the compound to an inactive placebo. These trials were applied in studies examining patient-reported experiences in adult males with varying degrees of erectile dysfunction severity. Research focused on outcomes reflecting daily functioning or activity level, measured using validated questionnaires like the International Index of Erectile Function (IIEF-EF score) and patient diaries, examining changes in measured erectile function and success rates.

Studies report how symptoms evolved in the observed populations, with descriptive measurements of IIEF-EF scores and successful completion rates in the Tadalafil groups compared to the placebo groups. Integrated analyses have been used to describe these patterns across diverse subgroups, including those with coexisting conditions such as diabetes mellitus and hypertension.


Evidence for Use in Benign Prostatic Hyperplasia (BPH) Symptoms

Research for Tadalafil in men with symptoms of BPH, known as Lower Urinary Tract Symptoms (LUTS), primarily involves short-to-intermediate-term placebo-controlled RCTs. These studies were used in research exploring how symptoms change over time in LUTS associated with BPH, a condition involving periods of heightened symptoms and functional limitations.

Studies report how symptoms evolved in the observed populations during the trial period, with descriptive patterns related to changes in the International Prostate Symptom Score (IPSS) and the associated Quality of Life (QoL) index. While studies monitored functional measures of the bladder, data show patterns related to these physical measures that were often inconsistent or comparable to the placebo groups across the evidence base.


What is Still Uncertain About Talys

Follow-up durations were limited in the most controlled settings (typically 12 to 16 weeks), meaning the certainty remains low regarding the effects far beyond one or two years. Long-term effects are not fully established through controlled research, and evidence for the durability and long-term maintenance of reported effects is still emerging. Comparative evidence for head-to-head trials against other similar agents is limited across all approved uses.

Key Studies & References

  1. Efficacy and Safety of 12-week Monotherapy With Once Daily 5 mg Tadalafil for Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: Evidence-based Analysis (Systematic Review/Meta-analysis)
  2. Tadalafil - StatPearls (Comprehensive Monograph on ED, BPH, and PAH indications)

Frequently Asked Questions (FAQ)

Common questions about Talys (FAQ)


Q: How does Talys compare to similar medications I've heard of?

A: Regulatory documents indicate that the active ingredient in Talys (Tadalafil) has a long duration of action compared to similar medicines. This is because it has a prolonged terminal half-life, which averages about 17.5 hours in healthy subjects. This pharmacological characteristic is noted in official documents as supporting its long duration of action.


Q: What are the most commonly reported side effects of Talys?

A: Official product information categorizes certain physiological responses reported during clinical studies based on frequency. The most commonly reported adverse reactions (≥ 2%) include headache, indigestion, back pain, muscle aches, nasal congestion, flushing, and pain in limbs. Dizziness is also listed as a common effect (1–10%).


Q: Is Talys safe to use during pregnancy or while breastfeeding?

A: For the treatment of approved conditions in adult men (ED and BPH), Talys is not indicated for use in women. For its use in Pulmonary Arterial Hypertension (PAH), official documents note that the drug should be used during pregnancy only if clearly necessary. Information in official documents notes it is not known if the active ingredient is excreted in human milk.


Q: Can Talys affect my mood or cause changes in behavior?

A: The common and frequent side effects listed in official product information primarily affect physical systems like the muscles, nerves, and vascular system. Official documents do not mention mood or behavioral changes (such as anxiety or depression) among the common adverse reactions reported in clinical trials.


Q: What is the difference between the 'active' and 'inactive' ingredients in Talys?

A: The active ingredient is Tadalafil, which is the substance responsible for producing the drug's intended pharmacological effect in the body. Inactive ingredients (also known as excipients) are standard components used to create the film-coated tablet's structure, stability, and appearance, but they do not have a therapeutic effect.


Q: Does Talys need to be taken with food, or can it be taken on an empty stomach?

A: According to official regulatory guidance, Talys may be taken with or without food for all approved uses. Clinical pharmacology studies indicate that the absorption is not significantly affected by taking it with food.


Q: Can Talys be used to treat other conditions not listed in the main description?

A: Official regulatory documents only list the approved conditions for Talys, which are Erectile Dysfunction (ED), Benign Prostatic Hyperplasia (BPH) symptoms, and Pulmonary Arterial Hypertension (PAH). Authoritative sources do not provide information or authorization for any other uses.


Q: Does Talys start working immediately, or does it take a few days?

A: After taking a single oral dose, official pharmacological studies indicate that the maximum concentration of the drug in the blood is typically reached between 30 minutes and 6 hours, with a median time of about 2 hours.


Q: How long does the effect of Talys typically last after taking it?

A: For the 'as-needed' regimen, clinical trial evidence indicates that the drug was effective in improving function compared to placebo for up to 36 hours following the dose. This is supported by the drug’s prolonged half-life.


Q: Is it normal to feel slightly dizzy or tired when starting Talys?

A: Official documents list dizziness as a common adverse reaction, which means it occurred in 1–10% of patients during clinical trials. Fatigue is not listed among the most common adverse reactions (≥ 2%). Official documents list dizziness as a common adverse reaction, but do not specifically address whether the effects are more noticeable when first starting the medication.


Q: Is it safe to take Talys if I am already taking supplements?

A: Official drug information focuses on interactions with prescription medicines that strongly affect the CYP3A4 enzyme (a key metabolic pathway) or those that can cause a drop in blood pressure. The possibility of an interaction depends on whether the supplement affects the CYP3A4 enzyme or blood pressure.


Q: Can Talys affect my ability to drive or operate machinery?

A: Official documents list dizziness as a common side effect. Patients should be aware of their response to the medication before driving or operating machinery.


Q: What should I do if I forget to take a dose of Talys?

A: If a dose is missed when taking the once-daily regimen, regulatory instructions advise patients to take the next dose at the regularly scheduled time. It is specifically noted that patients should not double the dose to make up for the missed tablet.


Q: Is Talys a controlled substance or habit-forming?

A: Official documents do not classify Talys as a controlled substance. Information regarding drug abuse or physical dependence is not listed in the product's official regulatory labeling.


Q: Is Talys approved for use in children or teenagers?

A: Talys is approved for use in adult men (18 years and older) for its ED and BPH indications. Official documents state that the safety and effectiveness have not been established in pediatric patients for any approved use.


Q: Is Talys available as a generic version?

A: The active ingredient in Talys is Tadalafil. Tadalafil has been approved by the FDA as the generic name for the drug substance. Generic versions of the active ingredient are available.


Q: Are there common signs that Talys is not working for me?

A: Efficacy in clinical research is measured through changes in specific functional outcomes, such as validated questionnaires like the IIEF-EF score. However, official drug labels do not list specific common signs for patients to monitor for lack of efficacy.


Q: Can I take Talys if I have a history of heart conditions?

A: The medicine is strictly contraindicated in men for whom sexual activity is inadvisable due to their underlying cardiovascular status. Official warnings state that caution is necessary in patients with specific recent cardiovascular events, such as a heart attack or stroke within the last six months.


Q: Does Talys have a risk of drug dependence or withdrawal effects?

A: Official product information regarding Drug Abuse and Dependence does not contain information regarding withdrawal effects upon cessation of use. The drug is not classified as a controlled substance.


Q: Is Talys used as a preventive measure for a disease?

A: Talys is approved for the treatment of three specific conditions: Erectile Dysfunction, Benign Prostatic Hyperplasia, and Pulmonary Arterial Hypertension. It is not indicated in official documents for use as a preventive measure against the onset of any disease.


Q: Can Talys interact with herbal remedies like St. John's Wort?

A: Official product information states that potent substances that induce the CYP3A4 enzyme (like Rifampin) can decrease the drug's overall exposure. Because St. John's Wort can also act as a potent CYP3A4 inducer, the possibility of a diminished pharmacological effect must be considered.


Q: What does the patient information leaflet say about overdose with Talys?

A: Official regulatory documents state that standard supportive measures are generally taken in cases of overdosage. Clinical trial data showed that adverse events seen in studies were similar to those seen at lower doses, but with an increased incidence and severity, including the risk of severe hypotension (very low blood pressure).

How should Talys be stored and disposed of?

How to Store and Dispose of Talys (Tadalafil)

Official regulatory guidelines strictly define the conditions necessary to maintain the stability and safety of Talys tablets.

Storage Conditions

The medicine must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). To ensure product integrity, the tablets must be protected from moisture and kept in the original container with the closure tightly sealed. It is mandatory to keep the medicine out of the sight and reach of children.

Disposal Instructions

Disposal of unused or expired Talys must be performed in accordance with local regulations. Regulatory guidance recommends utilizing drug take-back programs when available. The product should not be disposed of by flushing it down the toilet or into wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Talys found in:

A-Z Index: